Brief: Nuvectis Pharma's NXP900 Demonstrates Robust Activity In Non-Small Cell Lung Cancer Cell Lines
08/04/2024 14:02
April 8 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA'S NXP900 DEMONSTRATES ROBUST ACTIVITY IN
NON-SMALL CELL LUNG CANCER CELL LINES
* NUVECTIS PHARMA: HIGHLY SYNERGISTIC ANTIPROLIFERATIVE
ACTIVITY
IN EGFR-RESISTANT CELLS IN COMBINATION WITH OSIMERTINIB, ACTIVE
INGREDIENT IN TAGRISSO
* NUVECTIS PHARMA INC: SINGLE AGENT ANTIPROLIFERATIVE
ACTIVITY IN
CELLS RESISTANT TO ALECTINIB, ACTIVE INGREDIENT IN ALECENSA
Source text for Eikon: ID:nGNE8BKHBL
Further company coverage: NVCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin